Research indicates that the dysfunction of GPX3 expression in tumor cells is linked to a poor prognosis for patients with cancer and chemotherapeutic resistance 44, including endometrial adenocarcinoma 45, lung cancer 46, gastric cancer 47, prostate cancer 48, cervical cancer 49, and thyroid cancer 50. The gene discussed is GPX3; the disease is endometrium adenocarcinoma.